HC Wainwright Reiterates “Buy” Rating for CalciMedica (NASDAQ:CALC)

CalciMedica (NASDAQ:CALC)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a $16.00 target price on the stock.

CalciMedica Stock Performance

Shares of NASDAQ:CALC opened at $2.00 on Thursday. The company has a market cap of $27.94 million, a P/E ratio of -1.85 and a beta of 1.24. The stock’s 50-day moving average is $1.80 and its 200-day moving average is $2.55. CalciMedica has a 52-week low of $1.43 and a 52-week high of $6.02.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.07. As a group, equities analysts predict that CalciMedica will post -2.21 EPS for the current year.

Institutional Investors Weigh In On CalciMedica

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Deerfield Management Company L.P. Series C grew its position in shares of CalciMedica by 30.0% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 1,300,000 shares of the company’s stock valued at $4,602,000 after purchasing an additional 300,000 shares during the last quarter. Stonepine Capital Management LLC acquired a new stake in CalciMedica during the fourth quarter worth about $1,660,000. Alyeska Investment Group L.P. acquired a new stake in CalciMedica during the fourth quarter worth about $1,318,000. Wealthedge Investment Advisors LLC grew its position in CalciMedica by 289.3% during the first quarter. Wealthedge Investment Advisors LLC now owns 108,291 shares of the company’s stock worth $207,000 after buying an additional 80,472 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in CalciMedica by 36.5% during the fourth quarter. Geode Capital Management LLC now owns 90,866 shares of the company’s stock worth $322,000 after buying an additional 24,313 shares in the last quarter.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.